Effectiveness and side effects of pegylated interferon/ribavirin and direct acting antiviral: DAA in chronic hepatitis C patients in Lampang hospital
Keywords:
Effectiveness, Side effects, Chronic hepatitis C, Lampang hospitalAbstract
Background: Chronic hepatitis C is the major cause of cirrhosis and hepatoma. Currently, the treatment of hepatitis C has made great progress and direct acting antiviral (DAA) were available in Lampang hospital since 2018. The effectiveness and side effects of such therapy has not been investigated in Lampang hospital.
Objectives: To evaluate effectiveness and side effects of pegylated interferon/ribavirin and direct acting antiviral: DAA treatment in chronic hepatitis C patients in Lampang hospital.
Methods: A retrospective cohort study was conducted among chronic hepatitis C patients who underwent treatment at Lampang hospital between January 2018 and December 2019. Baseline characteristics, outcomes and side effects were collected using electronic database and analysis with descriptive statistics. Comparison characteristics between patient groups by using Chi-square or Fisher’s exact test as appropriate. Analysis factors affecting SVR and side effects by using exponential risk regression.
Results: There were 90 patients with the mean age of 53.3 ± 8.7 years, 53.3% were male, 31.1% were co-infected with HIV, 54.4% found cirrhosis, HCV genotype 1a (23.3%), 1b (16.7%), 3 (40%) and 6 (18.9%), mean baseline HCV RNA 5.6 ± 0.8 log10 IU/mL. Patients were treated with Peg-IFN/Ribavirin/Sofosbuvir 40%, Sofosbuvir/Ledipasvir 30% and Sofosbuvir/Ledipasvir/Ribavirin 30%. Sustained virological response (SVR) was 92.2%. Most common side effects were mild such as fever, anorexia and myalgia that were found 34%. Anemia, neutropenia and thrombocytopenia were found in 24.4%, 27.8% and 27.8% respectively. Co-infected with HIV did not affect the outcome of treatment. HCV genotype 3 with cirrhosis had the lowest SVR rate (81.8%) and tended to have side effects from treatment.
Conclusion: Treatment of chronic hepatitis C was effective in Lampang hospital. All chronic hepatitis C patients with complete inclusion criteria should be enrolled for treatment especially before cirrhosis occurs.
References
Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450-6.
Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, et al. Management of hepatitis C virus infection in the Asia-Pacific region. Lancet Gastroenterol Hepatol. 2017;2(1):52-62.
THASL Committee.Thailand practice guideline for management of chronic hepatitis C 2018. Thai J Hepatol. 2018;3(1):50-60.
European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392-420.
Wasitthankasem R, Vongpunsawad S, Siripon N, Suya C, Chulothok P, Chaiear K, et al. Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. PLoS One. 2015;10(5):e0126764.
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2017;66(1):153-194.
Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93.
Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64(6):1217-23.
Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol. 1996;31(4):552-8.
Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J med. 2006;355(23):2444-51.
Smolders EJ, Thammajaruk N, de Kanter CTMM, Colbers A, Chaiyahong P, Cuprasitrut T, et al. Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics. Trop Med Int Health. 2018;23(3):295-305.
Chotiyaputta W, Chamroonkul N, Bunchorntavakul C, Seansawat K, Techathuvanan K, Apisophonsiri P, et al. Efficacy of pegylated interferon and ribavirin for the treatment of chronic hepatitis C, genotype 3 patients in Thailand. J Med Assoc Thai. 2018;101(4):S127-34.
Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362(9397):1708-13.
Downloads
Published
How to Cite
Issue
Section
License
The articles that had been published in the journal is copyright of Journal of Nakornping hospital, Chiang Mai.
Contents and comments in the articles in Journal of Nakornping hospital are at owner’s responsibilities that editor team may not totally agree with.
